175 related articles for article (PubMed ID: 19360349)
1. 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
Kazuno H; Fujioka A; Fukushima M; Wataya Y; Matsuda A; Sasaki T
Int J Oncol; 2009 May; 34(5):1373-80. PubMed ID: 19360349
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil.
Kazuno H; Shimamoto Y; Tsujimoto H; Fukushima M; Matsuda A; Sasaki T
Oncol Rep; 2007 Jun; 17(6):1453-60. PubMed ID: 17487404
[TBL] [Abstract][Full Text] [Related]
3. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
[TBL] [Abstract][Full Text] [Related]
4. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.
Azuma A; Matsuda A; Sasaki T; Fukushima M
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):609-19. PubMed ID: 11563078
[TBL] [Abstract][Full Text] [Related]
5. Anticancer mechanisms of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106).
Naito T; Yokogawa T; Kim HS; Futagami M; Wataya Y; Matsuda A; Fukushima M; Kitade Y; Sasaki T
Nucleic Acids Res Suppl; 2002; (2):241-2. PubMed ID: 12903195
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect and mechanism of a novel multifunctional nucleoside, 3'-ethynylnucleoside, on human cancers].
Tanaka M; Tabata S; Matsuda A; Fukushima M; Eshima K; Sasaki T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):476-82. PubMed ID: 9063487
[TBL] [Abstract][Full Text] [Related]
7. 3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.
Fukushima H; Abe T; Sakamoto K; Tsujimoto H; Mizuarai S; Oie S
BMC Cancer; 2014 Aug; 14():562. PubMed ID: 25087851
[TBL] [Abstract][Full Text] [Related]
8. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
[TBL] [Abstract][Full Text] [Related]
9. Antitumor mechanisms and metabolism of the novel antitumor nucleoside analogues, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil.
Takatori S; Kanda H; Takenaka K; Wataya Y; Matsuda A; Fukushima M; Shimamoto Y; Tanaka M; Sasaki T
Cancer Chemother Pharmacol; 1999; 44(2):97-104. PubMed ID: 10412942
[TBL] [Abstract][Full Text] [Related]
10. Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Naito T; Yokogawa T; Takatori S; Goda K; Hiramoto A; Sato A; Kitade Y; Sasaki T; Matsuda A; Fukushima M; Wataya Y; Kim HS
Cancer Chemother Pharmacol; 2009 Apr; 63(5):837-50. PubMed ID: 18668243
[TBL] [Abstract][Full Text] [Related]
11. Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Kazuno H; Sakamoto K; Fujioka A; Fukushima M; Matsuda A; Sasaki T
Cancer Sci; 2005 May; 96(5):295-302. PubMed ID: 15904471
[TBL] [Abstract][Full Text] [Related]
12. Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
Hattori H; Nozawa E; Iino T; Yoshimura Y; Shuto S; Shimamoto Y; Nomura M; Fukushima M; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1998 Jul; 41(15):2892-902. PubMed ID: 9667977
[TBL] [Abstract][Full Text] [Related]
13. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
14. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA
Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Suzuki M; Endo M; Shinohara F; Echigo S; Rikiishi H
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1115-22. PubMed ID: 19280190
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Shimamoto Y; Fujioka A; Kazuno H; Murakami Y; Ohshimo H; Kato T; Matsuda A; Sasaki T; Fukushima M
Jpn J Cancer Res; 2001 Mar; 92(3):343-51. PubMed ID: 11267946
[TBL] [Abstract][Full Text] [Related]
17. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
Spugnini EP; Cardillo I; Verdina A; Crispi S; Saviozzi S; Calogero R; Nebbioso A; Altucci L; Cortese G; Galati R; Chien J; Shridhar V; Vincenzi B; Citro G; Cognetti F; Sacchi A; Baldi A
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6133-43. PubMed ID: 17062690
[TBL] [Abstract][Full Text] [Related]
18. A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides.
Murata D; Endo Y; Obata T; Sakamoto K; Syouji Y; Kadohira M; Matsuda A; Sasaki T
Drug Metab Dispos; 2004 Oct; 32(10):1178-82. PubMed ID: 15280220
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of apoptosis induced by 3'-ethynylcytidine.
Wataya Y; Naito T; Sato A; Hiramoto A; Kitade Y; Sasaki T; Matsuda A; Fukushima M; Kim HS
Nucleic Acids Symp Ser (Oxf); 2009; (53):291-2. PubMed ID: 19749375
[TBL] [Abstract][Full Text] [Related]
20. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]